This study reveals the dual regulatory role of IGSF10 in bone remodeling, providing a novel therapeutic target for treating osteoporosis and craniofacial defects, and suggesting that combined modulation of the EGFR pathway may optimize current bone regeneration strategies.
Literature Overview
The article titled 'IGSF10 regulates osteogenesis and osteoclastogenesis via a noncanonical EGFR–STAT1 signaling axis to promote skeletal regeneration,' published in the journal Bone Research, systematically investigates the function and molecular mechanisms of immunoglobulin superfamily member 10 (IGSF10) in bone metabolism and regeneration. Using multiple in vivo and in vitro models, the study confirms that IGSF10 promotes osteogenic differentiation while inhibiting osteoclastogenesis, acting through a noncanonical EGFR–STAT1 signaling pathway. This finding expands the regulatory network of IgSF proteins in the skeletal system and provides a theoretical basis for developing regenerative factors with dual functions of promoting bone formation and suppressing bone resorption.Background Knowledge
Bone remodeling relies on the dynamic balance between osteoblast-mediated bone formation and osteoclast-driven bone resorption. Imbalance leads to diseases such as osteoporosis and non-union fractures. Although bone morphogenetic protein 2 (BMP2), widely used in clinical settings, strongly induces osteogenesis, it fails to suppress osteoclast activity, often requiring high doses that cause side effects such as ectopic ossification and inflammation. Therefore, developing novel factors capable of coordinately regulating both pathways is a major goal in regenerative medicine.
Although pathways such as RANKL/OPG and Wnt/sclerostin have been implicated in bone metabolism, their pleiotropy and complex feedback mechanisms limit targeted applications. IGSF10 was previously associated with cleidocranial dysplasia and highly expressed in fracture healing regions, suggesting a potential role in bone repair. However, direct evidence for its function and mechanism in bone cells has been lacking. This study fills that knowledge gap by systematically investigating whether IGSF10 can act as a novel 'coupling factor' to coordinate bone formation and resorption, thereby addressing a critical mechanistic void in the field.
Research Methods and Experiments
The authors generated an inducible IGSF10 knockout mouse model (Igsf10KO) and used micro-CT, histological staining, and molecular assays to systematically evaluate its role in overall skeletal development. Results showed that KO mice exhibited significantly reduced bone mass, decreased osteoblast surface, and increased osteoclast surface, indicating that IGSF10 deficiency leads to reduced bone formation and enhanced bone resorption. Further in vitro experiments using bone marrow mesenchymal stem cells (BMSCs) and bone marrow monocytes (BMMs) confirmed that IGSF10 restores osteogenic capacity in KO cells and suppresses osteoclast differentiation.
To explore the underlying mechanisms, the authors employed RNA-seq, Co-IP, molecular docking, and signaling pathway inhibitors. RNA-seq revealed that IGSF10 activates the JAK-STAT pathway rather than the canonical BMP/Smad pathway. Co-IP and molecular docking confirmed that IGSF10 directly binds EGFR, and the EGFR inhibitor PD153035 blocked its osteogenic effects, establishing EGFR as a key receptor. Notably, IGSF10 promotes osteogenesis via the EGFR–STAT1 axis, but in osteoclasts, it acts through EGFR without activating STAT1, suggesting cell-type-specific downstream mechanisms.Key Conclusions and Perspectives
Research Significance and Prospects
This study establishes IGSF10 as a novel 'coupling factor' in bone remodeling, with dual functionality surpassing traditional unidirectional regulators. From a drug development perspective, targeting IGSF10 or its downstream EGFR–STAT1 axis could yield new therapeutics that simultaneously promote bone formation and inhibit resorption, particularly beneficial for diseases like osteoporosis and bone defects requiring long-term remodeling balance.
In disease modeling, IGSF10 mutant individuals or humanized models could be leveraged to study its role in skeletal disorders such as cleidocranial dysplasia. Moreover, its potent osteogenic activity in human periodontal ligament cells (PDLCs) highlights its potential in periodontal regeneration and dental implant osseointegration, warranting further large-animal studies.
Conclusion
This study establishes IGSF10 as a rising star in bone regeneration, coordinating osteogenesis and osteoclastogenesis through a noncanonical EGFR–STAT1 pathway, achieving precise 'one-target, dual-effect' regulation. Compared to existing factors like BMP2, IGSF10 offers both bone-forming and anti-resorptive functions and acts synergistically with BMP2, significantly reducing dose-dependent risks in clinical applications. From bench to bedside, this discovery offers novel therapeutic strategies for osteoporosis, craniofacial defects, periodontal disease, and related conditions. Future development of recombinant IGSF10 protein or small-molecule mimetics, combined with advanced delivery systems, may enable localized precision interventions and reshape clinical approaches to bone repair. Furthermore, its high efficacy in PDLCs underscores unique advantages in oral regenerative medicine, potentially positioning IGSF10 as an additive in next-generation biomaterials. In sum, IGSF10 not only expands the functional landscape of IgSF proteins but also represents a paradigm shift in regenerative therapy—from 'enhancing single pathways' to 'coordinating dual pathways'—with profound translational implications.
